2seventy bio (TSVT) News Today

Healthcare of Ontario Pension Plan Trust Fund cut its stake in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 15.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,468,500 shares of the company's stock

Marshall Wace LLP boosted its stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 50.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 667,023 shares of the company's stock after purchasing an a

2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totalling 5,130,000 shares, a decline of 13.8% from the August 31st total of 5,950,000 shares. Approximately 10.6% of the shares of the company are sold short. Based on an average daily volume of 402,300 shares, the days-to-cover ratio is presently 12.8 days.

2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, four hav

Venator Management LLC boosted its position in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 49.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 485,000 shares of the company's stock after acqui

2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, four have given a

2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) insider Jessica Snow sold 7,816 shares of the firm's stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $4.32, for a total transaction of $33,765.12. Following the completion of the transaction, the insider now owns 156,330 shares in the company, valued at approximately $675,345.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Vanguard Group Inc. lessened its holdings in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 6.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,731,679 shares of the company's stock after selling 254,091 share

2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommend

2seventy bio (NASDAQ:TSVT) will be releasing earnings before the market opens on Wednesday, August 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=617700)

Jacobs Levy Equity Management Inc. bought a new stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 379,586 shares of the company's stock, valued at appro

Morgan Stanley decreased their price objective on shares of 2seventy bio from $7.00 to $6.00 and set an "equal weight" rating for the company in a report on Monday.

2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 7,290,000 shares, a growth of 24.4% from the June 30th total of 5,860,000 shares. Based on an average daily volume of 558,400 shares, the short-interest ratio is currently 13.1 days. Approximately 15.2% of the company's shares are short sold.

Healthcare of Ontario Pension Plan Trust Fund bought a new position in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,736,600 shares o

Susquehanna Fundamental Investments LLC purchased a new stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 138,243 shares of the company's stock, v

Wellington Management Group LLP decreased its stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 82.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 515,955 shares of the company's stock after selling 2,478,516 shares during the

Wedbush reiterated a "neutral" rating and issued a $5.00 price objective on shares of 2seventy bio in a research report on Thursday.

Goldman Sachs Group Inc. boosted its holdings in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 512.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,508,800 shares of the company's stock after acquiring

2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recomm

Madison Avenue Partners LP lifted its stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 17.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,754,788 shares of the company's stock after purchasing

Engine Capital Management LP grew its stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 337.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,494,304 shares of the company's stock after purchasing an ad

The Goldman Sachs Group downgraded shares of 2seventy bio from a "neutral" rating to a "sell" rating and dropped their price target for the stock from $5.00 to $2.00 in a research report on Thursday.

2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has g